Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs

AIDS

Volumn 15, Issue 12, 2001, Pages 1471-1475

  Dunne, Amanda L ^a   Mitchell, Fiona M ^a   Coberly, Suzanne K ^b   Hellmann, Nicholas S ^c   Hoy, Jennifer ^d   Mijch, Anne ^d   Petropoulos, Christos J ^c   Mills, John ^a   Crowe, Suzanne M ^a,e  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b APPLIED BIOSYSTEMS   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d ALFRED HOSPITAL   (Australia)

^e NONE   (Australia)

Author keywords

Genotype; HIV 1; Phenotype; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; STRAIN DIFFERENCE; VALIDATION PROCESS; VIRUS INHIBITION; VIRUS LOAD;

EID: 0035902986     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200108170-00003     Document Type: Article

References (9)

1. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
2. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
3. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
4. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine
5. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors
6. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain
7. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants